A positron emission tomography study to assess binding of lecozotan, a novel 5-hydroxytryptamine-1A silent antagonist, to brain 5-HT1A receptors in healthy young and elderly subjects, and in patients with Alzheimer's disease

Clinical Pharmacology and Therapeutics

Volumn 83, Issue 1, 2008, Pages 86-96

  Raje, S ^a   Patat, A A ^b   Parks, V ^c   Schechter, L ^d   Plotka, A ^a   Paul, J ^a   Langstrom, B ^e  

^a PFIZER INC   (United States)

^b Biotrial   (France)

^c Clinical Research and Development   (France)

^d Chemical and Screening Sciences   (United States)

^e Uppsala Imanet   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN RECEPTOR; CARBON 11; LECOZOTAN; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN 1A RECEPTOR;

ADULT; AGED; ALZHEIMER DISEASE; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CEREBELLUM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG RECEPTOR BINDING; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG UPTAKE; ELECTROCARDIOGRAM; FEMALE; GERIATRIC PATIENT; GROUPS BY AGE; HUMAN; ISOTOPE LABELING; LABORATORY TEST; MALE; MAXIMUM PLASMA CONCENTRATION; MESENCEPHALON; MOLECULAR MODEL; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; SIDE EFFECT; SIMULATION; SINGLE DRUG DOSE; STEADY STATE; TEMPORAL CORTEX; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; VITAL SIGN;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; BRAIN; CARBON RADIOISOTOPES; COMPUTER SIMULATION; DIOXANES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; PYRIDINES; RADIOPHARMACEUTICALS; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN ANTAGONISTS; TIME FACTORS;

EID: 37649006241     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100232     Document Type: Article

References (30)

1. Bowen, D.M., Francis, P.T., Chessell, I.P. & Webster, M.T. Neurotransmission - the link integrating Alzheimer research? Trends Neurosci. 17, 149-150 (1994).
2. 3H] 8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia. Neurochem. Int. 30, 565-574 (1997).
3. 11C]WAY-100635. Brain Res. 745, 96-108 (1997).
4. 1B binding sites in bovine brain. Brain Res. 344, 167-171 (1985).
5. Pazos, A., Hoyer, D., Dietl, M.M. & Palacios, J.M. Autoradiography of serotonin receptors. In Neuronal Serotonin (eds. Osborne, N.N. & Hamon, M.) 507-543 (John Wiley and Sons, Chichister, UK, 1988).
6. VanderMaelen, C.P., Matheson, G.K., Wilderman, R.C. & Patterson, L.A. Inhibition of serotonergic dorsal raphe neurons by systemic and ionophoretic administration of buspirone, a non-bensodiazepine anxiolytic drug. Eur. J. Pharmacol. 129, 123-130 (1986).
7. 1A reduces 5-hydroxytryptamine release in rat hippocampus in vivo as determined by brain microdialysis. Br. J. Pharmacol. 96, 283-290 (1989).
8. Adell, A. & Artigas, F. Differential effects of clomipramine given locally or systemically on extracellular 5-hydroxytryptamine in raphe nuclei and frontal cortex. Naunyn-Schmiedeberg's Arch. Pharmacol. 343, 237-244 (1991).
9. Invernizzi, R., Belli, S. & Samanin, R. Citalopram's ability to increase the extracellular concentrations of serotonin in the dorsal raphe prevents the drug's effect in the frontal cortex. Brain Res. 584, 322-324 (1992).
10. Schechter, L.E. et al. Lecozotan (SRA-333): a selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties. J. Pharmacol. Exp. Ther. 314, 1274-1289 (2005).
11. Patat, A., Parks, V., Raje, S., Plotka, A. & Chassard, D. Safety, pharmacokinetics (PK) and pharmacodynamics of ascending single doses of SRA-333 in healthy subjects. J. Clin. Pharm. 75, 21 (2004).
12. Patat, A., Parks, V., Raje, S., Plotka, A. & Chassard, D. Safety, pharmacokinetics and pharmacodynamics of ascending multiple doses of SRA-333 in healthy subjects. Clin. Pharmacol. Ther. 75, 21 (2004).
13. 11C] WAY-100635. Eur. J. Pharmacol. 301, R5-R7 (1996).
14. 11C]WAY-100635 - explanation of high signal content in PET and an aid to biomathematical modeling. Nucl. Med. Biol. 25, 215-223 (1998).
15. Andersson, J.L.R. A rapid and accurate method to realign PET scans utilizing image edge transformation. J. Nucl. Med. 36, 657-669 (1995).
16. Wada, H. Blood-brain barrier permeability of the demented elderly as studied by cerebrospinal fluid-serum albumin ratio. Inter. Med. 37, 509-513 (1998).
17. Claudio, L. Ultrastructural features of the blood-brain barrier in biopsy tissue from Alzheimer's disease patients. Acta Neuropathol. (Berl) 91, 6-14 (1996).
18. Alafuzoff, I., Adolfsson, R., Grundke-Iqbal, I. & Winblad, B. Blood-brain barrier in Alzheimer dementia and in non-demented elderly. An immunocytochemical study. Acta Neuropathol. (Berl) 73, 160-166 (1987).
19. Mooradian, A.D. Effect of aging on the blood-brain barrier. Neurobiol. Aging 9, 31-39 (1988).
20. 1A receptor binding potential during a major depressive episode predicts poor treatment response: preliminary data from a naturalistic study. Neuropsychopharmacology 31, 1745-1749 (2006).
21. 11C]WAY-100635 binding to 5-HT1A receptors in normal male volunteers: normative data and relationship to methodological, demographic, physiological, and behavioral variables. Neuroimage 15, 620-632 (2002).
22. 1A antagonist in healthy elderly subjects. Clin. Pharmacol. Ther. 79, p68 (2006).
23. 1A receptors in humans: preliminary analyses. Nuci. Med. Biol. 27, 523-527 (2000).
24. 1A antagonist. Clin. Pharmacol. Ther. 77, 29 (2004).
25. 1A antagonist. Clin. Pharmacol. Ther. 77, P29 (2005).
26. Lammertsma, A.A. & Hume, S.P. Simplified reference tissue model for PET receptor studies. Neuroimage 4, 153-158 (1996).
27. 11C] WAY-100635 for PET. Neuroimage 8, 426-440 (1998).
28. Jusko, W.J. Guidelines for collection and analysis of pharmacokinetic data. In Applied Pharmacokinetics - Principles of Therapeutic Drug Monitoring 3rd edn. (eds. Vans, W.E., Schentag, J.J. & Jusko, W.J.) 2-1-2-43 (Applied Therapeutics, Vancouver, 1992 ).
29. Andree, B., Hedman, A., Thorberg, S., Nilsson, D., Halldin, C. & Farde, L. Positron emission tomographic analysis of dose-dependent NAD-299 binding to 5-hydroxytryptamine1A receptors in the human brain. Psychopharmacology 167, 37-45 (2003).
30. 3H]-N-(2-(4-(2-methoxyphenyl)-1- piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide trihydrochloride (WAY-100635) positron emission tomography study in humans. J. Pharmacol. Exp. Ther. 301, 1144-1150 (2002).